Document text
Principal Investigator: Cody Carrell
Organization: SALUS DISCOVERY, LLC
Fiscal Year: 2024
Award: $300,000
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT
Mycobacterium tuberculosis (TB) is a global threat to human health and accounts for 20% of adult deaths in low-
income countries (~1.6 million deaths/year), yet only ~23% of new TB patients receive a WHO recommended
nucleic acid test, while 37% receive tests with significantly lower sensitivity (e.g., smear microscopy), and ~40%
cases do not have access to testing. The critical gap in TB diagnostics, and the weakest link in global TB care,
is access to high-quality TB testing. In order to address this, the WHO has developed target product profiles for
the highest-priority TB diagnostic technologies and key among them is an affordable (<$2) urine-based antigen
test (e.g., lateral flow assay or LFA) for point-of-care (POC) testing in low resource settings. An accurate urine-
based antigen test that can provide both simplicity (add-wait-read operation) and low cost (<$2) has the potential
to close the immense gap in access to quality TB testing.
However, the only recommended and commercially available urine LFA for TB is the Determine TB LAM (DTB-
LAM) antigen test from Abbott. While high specificity enables use of the DTB-LAM test as a diagnostic, its limited
sensitivity has restricted its recommended use to severely immunocompromised populations (e.g., HIV+) (~10%
of all TB patients). More expensive LFA technologies like the FujiFilm TB LAM LFA with silver amplification
(~$8/test) and the ultra-sensitive electrochemiluminescence ELISA (ECL) ($10k instrument) platforms can offer
improved limits of detection (~50 fold lower than the DTB-LAM LFA) and generally improve clinical sensitivity
without compromising specificity, but they have similarly fallen short with immunocompetent patients.
To overcome this unmet need, Salus has recently developed the new Flow Direct assay, an affordable (<$2)
LFA-based, next-generation POC immunoassay that, similar to Abbott’s DTB-LAM and FujiFilm’s TB LAM
assays, targets LAM. However, Flow Direct reaches beyond Abbott’s and FujulFilm’s capabilities by providing:
of on-device removal of inhibitory urine matrix components, a visual readout, multiplexing with multiple Abs, and
a similar (or better) LOD than the ultrasensitive ECL laboratory instrument (i.e., < 10 pg/mL of LAM). Briefly,
through removal of inhibitory urine matrix components, Salus has now demonstrated the ability to detect LAM in
both HIV- AND HIV+ samples that falsely test negative by ultra-sensitive ECL, meaning Flow Direct has the
potential to be a single LFA-based test that can accurately diagnose TB in the vast majority of patients.
Here we propose to demonstrate the value of Flow Direct for TB urine LAM by completing the following Aims: In
Aim 1 (Phase I), screening, optimizing, and benchmarking membrane-based matrix removal from TB- spiked
samples; In Aim 2 (Phase I), performing verification of on-device matrix removal from spiked TB+ and TB-
samples; in Aim 3 (Phase II), finalizing the flow assay and device manufacturing for clinical evaluations; and in
Aim 4 (Phase II), evaluating the Flow device both in bio-banked clinical samples and in-country. Results will be
important to subsequent funding efforts for Flow Direct commercial development.
Terms: <21+ years old><AIDS Virus><Abscission><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adult><Adult Human><Ag element><Assay><Benchmarking><Best Practice Analysis><Bioassay><Biological Assay><COVID-19><CV-19><Cambodia><Caring><Cessation of life><Clinical><Clinical Evaluation><Clinical Sensitivity><Clinical Testing><Communicable Diseases><Coronavirus Infectious Disease 2019><Country><Data><Death><Dental Pulp><Detection><Development><Device Removal><Devices><Diagnostic><Diagnostic Reagent Kits><Diagnostic tests><Disease><Disorder><ELISA><Environment><Enzyme-Linked Immunosorbent Assay><Ethiopia><Evaluation><Excision><Extirpation><Filamentous Fungi><Filtration><Filtration Fractionation><Formulation><Funding><Geographic Area><Geographic Locations><Geographic Region><Geographical Location><Goals><HIV><Health><Human><Human Immunodeficiency Viruses><Immunoassay><Immunocompetent><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunosuppressed Host><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Instruction><Kampuchea><Khmer Republic><LAV-HTLV-III><LMIC><Laboratories><Link><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Lymphadenopathy-Associated Virus><M tb><M tuberculosis><M tuberculosis infection><M. tb><M. tb infection><M. tuberculosis><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MTB infection><Membrane><Methods><Microscopy><Modern Man><Molds><Mycobacterium tuberculosis><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><Nucleic Acid Amplification Tests><Nucleic Acid Testing><Patients><Performance><Phase><Population><Preparation><Recommendation><Removal><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-limited setting><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><Sampling><Silver><Site><Specificity><Surgical Removal><Syringes><TB diagnosis><TB diagnostics><TB infection><Technology><Testing><Tuberculosis><Tuberculosis diagnosis><Urine><Virus-HIV><Visual><World Health Organization><access gaps><accurate diagnosis><adulthood><antigen based detection><antigen based test><antigen detection><antigen test><benchmark><biobank><biorepository><clinical test><commercialization><coronavirus disease 2019><coronavirus disease-19><coronavirus infectious disease-19><cost><detect antigen><detection limit><developmental><diagnosed with TB><diagnosed with Tuberculosis><diagnostic kit><diagnostic technologies><disseminated TB><disseminated tuberculosis><enzyme linked immunoassay><gaps in access><geographic site><immune competent><immunosuppressed patient><improved><infection due to Mycobacterium tuberculosis><instrument><lateral flow assay><lateral flow test><low and middle-income countries><low income country><manufacture><manufacturing process><membrane structure><mtb><next generation><novel><operation><operations><point of care><point of care testing><point-of-care diagnostics><preparations><pulp><research clinical testing><resection><screening><screenings><test kit><tuberculosis diagnostics><tuberculosis infection><tuberculous spondyloarthropathy>